SIPULEUCEL-T (PROVENGE)

Course overview

Sipuleucel-T is U.S. FDA-approved to treat asymptomatic/minimally symptomatic metastatic hormone-resistant prostate cancer. It is for autologous use only, and is not screened for transmissible infectious disease. This continuing education module is designed to give the reader/learner an increased understanding of sipuleucel-T. Readers may explore any or all of the topics. One contact hour of continuing education credit is available for those who successfully complete the post-test and evaluation form.